NanoViricides Inc., a clinical stage company specializing in the development of broad-spectrum antivirals, has announced the potential of its drug candidate NV-387 to address the increasing global cases of measles. NV-387 has shown effectiveness and safety in animal model studies, specifically in humanized h-CD150+ knock-in mice, and has completed a Phase I clinical trial with no adverse events reported. The company is considering pursuing a "Fast Track" designation for NV-387, which could expedite its approval process. Measles is categorized as a rare orphan disease in the USA, potentially qualifying NV-387 for Orphan Drug Designation, offering benefits such as tax credits and market exclusivity. There is currently no approved drug for the treatment of measles. The results of the NV-387 studies have already been presented by NanoViricides.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.